Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

This course offers a strong foundation for careers in a range of educational settings, both public and private, in the UK or abroad. This course offers a strong foundation for careers in a range of ...

In a report released today, Gena Wang from Barclays maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $418.00. The company’s shares closed ...

Mnwabisi Mbangata arrived at Vertex Pharmaceuticals almost two years ago with nearly a decade of experience — including five years at Eli Lilly in various roles — in bringing innovative therapies to ...

and before that in the Federal Reserve Bank of Boston. While succession planning is often a difficult part of the retirement process, Munnell said that in this case, her replacement was a no-brainer.

If successful, the drug developed by Vertex Pharmaceuticals would offer a possible ... a senior vice president at Boston-based Vertex, said of suzetrigine in an interview in the fall.